氨氯地平联合替米沙坦或复方阿米洛利的疗效及安全性比较  

Comparison of Efficacy and Safety of Amlodipine Besylate Combined with Telmisartan and Amlodipine Besylate Amiloride Compound in Patients with Essential Hypertension

作　　者：舒瑛[1] 张艳梅[1] 陈复琼[1] 唐家荣[1] 汪道文[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院心内科,武汉430030

出　　处：《药物流行病学杂志》2011年第6期275-278,共4页Chinese Journal of Pharmacoepidemiology

基　　金：湖北省卫生厅科研基金重点项目(编号:JX3A07)

摘　　要：目的:比较氨氯地平联合替米沙坦和氨氯地平联合复方阿米洛利对轻中度原发性高血压患者的降压疗效和不良反应。方法:选择96例轻、中度原发性高血压患者,按随机及平行对照原则分为氨氯地平/复方阿米洛利组(A组)48例和氨氯地平/替米沙坦组(B组)48例,分别观察两组降压疗效,血生化指标影响及不良反应。观察时间12个月。结果:两组用药后收缩压和舒张压均有显著下降,组间比较差异无统计学意义(P>0.05)。两组治疗前后肝、肾功能及血糖等指标均无变化。A组治疗6月时血钾无变化,12月时血钾升高,6月和12月时尿酸均较入组时明显升高(P<0.05);B组治疗6月和12月时血钾及尿酸较入组时均无明显变化。B组不良反应发生率明显低于A组(P<0.05)。结论:氨氯地平联合替米沙坦与氨氯地平联合复方阿米洛利均有显著的降压效果。氨氯地平联合复方阿米洛利组不良反应发生率明显高于氨氯地平联合替米沙坦组。氨氯地平联合替米沙坦是更优化的联合治疗方案。Objective：To evaluate the efficacy and safety of amlodipine besylate combined with telmisartan and amlodipine besylate combined with arniloride compound in patients with mild and moderate essential hypertension. Method ：96 patients with essential hypertension were randomly divided into two groups. Group A （n = 48 ） was given amlodipine besylate and amiloride compound and Group B （ n = 48 ） was administrated with amlodipine besylate and telmisartan. After the administration their blood pressure and heart rates were followed up and their blood samples were taken for such biochemical indicators as uric acid, creatinine, potassium. The observation time was 12 months. Reset：First, after the administration the systolic and diastolic blood pressures were significantly lowered in the two groups but there was no significant difference between them （ P 〉 0.05 ）. Secondly, their liver and renal functions, blood glucose and other indicators did not change in the two groups before and after the treatment. 6 months after the treatment, Group A ＇ s serum potassium did not show any change, but significantly increased after 12 months. 6 and 12 months after the treatment their uric acids were more significantly increased than those of the income group （P 〈 0.05）. After Group B was treated for 6 and 12 months,their potassium and uric acid had no statistical differences when compared with their incoming. And thirdly, the incidence of adverse reactions in Group B were significantly less than that in Group A （ P 〈 0.05 ）. Conclusion： had equally good effect on hypertension but no effect on their heart rates, and there was no difference in antihypertensive effect on the two groups. The incidence of adverse reactions in the group using amlodipine besylate combined with telmisartan was signifi- cantly less than that of the group using amlodipine besylate combined with amiloride. Amlodipine besylate combined with telmisartan is a more optimal combined treatment.

关 键 词：苯磺酸氨氯地平 替米沙坦 复方阿米洛利 原发性高血压 联合治疗 

分 类 号：R972.4[医药卫生—药品]